ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1302

Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study

Daniel Solomon1, Olga Demler2, Pamela Rist2, Leah Santacroce1, Jon Giles3, Katherine Liao1 and Joan Bathon3, 1Brigham and Women's Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Columbia University, New York, NY

Meeting: ACR Convergence 2023

Keywords: Biomarkers, Cardiovascular, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiovascular (CV) disease remains an important source of morbidity and the most common cause of mortality in patients with rheumatoid arthritis (RA). It has been well recognized that traditional risk models for CV events do not perform well in RA patients. Prior attempts to improve risk prediction have not explored a wide range of candidate biomarkers shown in prior literature to be associated with both RA and CV disease. These analyses tested a wide range of candidate biomarkers against CV risk assessed by arterial inflammation using a FDG PET/CT scan at baseline and 24 weeks.

Methods: These analyses leveraged data from TARGET trial (NCT02374021). Subjects had RA and were inadequate responders to methotrexate (MTX); they were then randomized to add a TNF inhibitor or triple therapy (MTX + sulfasalazine + hydroxychloroquine). Both treatment strategies demonstrated significant suppression of arterial inflammation, measured as the change in target to background ratio in the most diseased segment (MDS TBR) on the FDG PET/CT. However, we observed no significant differences in change in arterial inflammation between the arms. In this analysis, both arms were combined into a single cohort and candidate biomarkers (see Table 1) were tested at baseline and 24 weeks. First, progressively adjusted models tested baseline candidate biomarker values (per standard deviation) as predictors of change in MDS TBR between baseline and 24 weeks. Second, change (also 0 to 24 weeks) in candidate biomarker values (per standard deviation) were tested against change in MDS TBR. Models with only biomarkers, only traditional CV risk factors (Pooled Cohort Equation), and both were tested.

Results: 115 patients had both biomarker data and FDG PET/CT data at baseline and 24 weeks. The patients in TARGET were similar to typical RA patients: 58-year median age; 71% women; 16 months median duration RA; and baseline DAS28 4.8. From the candidate biomarkers tested, we found significant adjusted associations between baseline values of SAA (b = -0.18, 95% CI -0.35, -0.01), CRP (b = 0.19, 95% CI 0.00, 0.38), and YKL-40 (b = 0.14, 95% CI 0.04, 0.25) (see Table 1) and change in arterial inflammation. We found significant adjusted associations between change from baseline to 24 weeks and change in MDS TBR for the following biomarkers (see Table 2): serum apolipoprotein A1 (b = -0.14, 95% CI -0.28, -0.01) and MMP-1 (b = 0.16, 95% CI -0.30, -0.02). Model fit (R2 and Root Mean Square Error, RMSE) was substantially improved when biomarkers were added to traditional CV risk factors.

Conclusion: A broad candidate biomarker scan among patients with RA demonstrated statistically and potentially clinically significant associations with change in arterial inflammation on FDG PET/CT. These biomarkers will be further tested in a large clinical RA cohort with confirmed CV events.

Supporting image 1

Supporting image 2


Disclosures: D. Solomon: CorEvitas, 5, Janssen, 5, moderna, 5, Novartis, 5, UpToDate, 9; O. Demler: None; P. Rist: None; L. Santacroce: None; J. Giles: AbbVie, 2, Eli Lilly, 2, Gilead, 2, Novartis, 2, Pfizer, 2; K. Liao: UCB, 2; J. Bathon: None.

To cite this abstract in AMA style:

Solomon D, Demler O, Rist P, Santacroce L, Giles J, Liao K, Bathon J. Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/biomarkers-of-cardiovascular-risk-in-patients-with-rheumatoid-arthritis-results-from-the-target-trial-biomarker-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biomarkers-of-cardiovascular-risk-in-patients-with-rheumatoid-arthritis-results-from-the-target-trial-biomarker-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology